USP10 as a Potential Therapeutic Target in Human Cancers.
USP10 as a Potential Therapeutic Target in Human Cancers.
复制标题
作者：
去泛素化是蛋白质翻译后修饰的一种主要形式，参与调节蛋白质的动态平衡和各种细胞过程。脱泛素化酶(DUBS)由大约5个亚家族成员组成，是脱泛素化的关键分子。USP10是一个USP家族的配音，具有经典的USP结构域，执行去泛素化。新出现的证据表明，USP10在人类癌症中是一把双刃剑。然而，其在肿瘤发生中不同作用的确切分子机制仍不清楚。一个可能的原因是对小区上下文的依赖。在这篇综述中，我们综述了USP10的下游底物和上游调节因子，以及它在多种人类癌症中作为癌基因和肿瘤抑制因子的双重作用。此外，我们还总结了多种药理作用的USP10抑制剂，包括小分子抑制剂，如spautin-1，以及中药。综上所述，基于USP10的S致癌作用，针对不同的肿瘤类型，开发特异而有效的USP10抑制剂可能是一种很有前途的治疗策略。
Deubiquitination is a major form of post-translational protein modification involved in the regulation of protein homeostasis and various cellular processes. Deubiquitinating enzymes (DUBs), comprising about five subfamily members, are key players in deubiquitination. USP10 is a USP-family DUB featuring the classic USP domain, which performs deubiquitination. Emerging evidence has demonstrated that USP10 is a double-edged sword in human cancers. However, the precise molecular mechanisms underlying its different effects in tumorigenesis remain elusive. A possible reason is dependence on the cell context. In this review, we summarize the downstream substrates and upstream regulators of USP10 as well as its dual role as an oncogene and tumor suppressor in various human cancers. Furthermore, we summarize multiple pharmacological USP10 inhibitors, including small-molecule inhibitors, such as spautin-1, and traditional Chinese medicines. Taken together, the development of specific and efficient USP10 inhibitors based on USP10’s oncogenic role and for different cancer types could be a promising therapeutic strategy.
DOI：
10.3390/ijerph18147594
发表时间：
2021-07-16
影响因子：
--
作者：
Huang D;Tao H;Wu Q;Huang SY;Xiao Y
通讯作者：
Xiao Y